Clinical trials: Antipsychotic
Alcohol Relapse Prevention, Alcoholism
Quetiapine vs. Placebo in Alcohol Relapse Prevention - a Pilot Study
Due to Quetiapine's particulars and the promising receptor profile, we want to examine the efficacy concerning relapse prevention of alcoholics suffering from persisting craving and/or affective symptoms (persisting sleep…
- Conditions
- Alcohol Relapse Prevention, Alcoholism, Alcohol Drinking, Alcohol Consumption
- Trial name
- NCT00561587
- Testing
- Seroquel®
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Schizophrenia
A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia
The primary objective of this study is to evaluate the efficacy of seroquel in the treatment of patients with acute schizophrenia compared with risperidone by evaluating the change of PANSS total score from the baseline to week 6.
- Trial name
- NCT00817648
- Testing
- Quetiapine, risperidone
- Where
- 4 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Antipsychotic Polypharmacy in Schizophrenia
The literature suggests that when a patient is prescribed more than one antipsychotic for at least 30 days, he or she is likely to continue on that combination.
- Trial name
- NCT00493233
- Testing
- 2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Centre for Addiction and Mental Health
Metabolic Disturbance, Hyperprolactinemia
Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment
The goal of this clinical trial is to explore the potential of metformin in managing olanzapine-induced metabolic disturbance and hyperprolactinemia in patients with schizophrenia. The main questions it aims to answer are: 1.
- Conditions
- Metabolic Disturbance, Hyperprolactinemia, Schizophrenia
- Trial name
- NCT06326840
- Testing
- Metformin
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Taipei Medical University Hospital
Schizophrenia, Schizophrenia Relapse
3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
This open-label, non-randomized, prospective study will evaluate the risk of symptoms recurrence during the three years after antipsychotic discontinuation in a sample of functionally recovered first-episode patients with…
- Conditions
- Schizophrenia, Schizophrenia Relapse, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- ADARFEP (NCT02220504)
- Testing
- Antipsychotic treatment discontinuation, Maintenance antipsychotic treatment
- Where
- Spain
- Volunteers
- 68 people
- Sponsor
- Fundación Marques de Valdecilla
Tardive Dyskinesia
Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents
Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in outpatient psychiatry practices in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one…
- Trial name
- RE-Kinect (NCT03062033)
- Where
- 34 sites in United States
- Volunteers
- 70 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia, Bipolar Disorder
Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders
The purpose of this study is to investigate the efficacy and safety of long-term psychopharmacotherapy in schizophrenia or bipolar disorder in terms of psychopathology and side effects.
- Trial name
- NCT00330226
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Seoul National University Hospital
Schizophrenia, Psychotic Disorders
A Registry of Treatment Adherence for Patients With Schizophrenia
The purpose of the study is to assess demographic, treatment, and outcome data in schizophrenia patients receiving treatment with long-acting injectable, tablet, or liquid formulations of first generation (conventional) or second…
- Trial name
- NCT00283517
- Testing
- antipsychotics
- Volunteers
- 2,046 people
- Sponsor
- Janssen-Cilag, S.A.
Dyskinesia, Drug-Induced
Movement Disorders Caused by Antipsychotic Drugs in Older Patients
This study will assess the risk of experiencing tardive dyskinesia and other movement disturbances associated with three atypical antipsychotic drugs among middle-aged and elderly psychiatric patients.
- Trial name
- NCT00255879
- Testing
- Quetiapine, Risperidone, Olanzapine
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of California, San Diego
Schizophrenia
Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
The purpose of this study is to assess the efficacy (how well the drug works; primarily through the time to relapse) of long-acting injectable paliperidone palmitate compared to treatment as usual with orally administered…
- Trial name
- PROSIPAL (NCT01081769)
- Testing
- paliperidone palmitate injection, oral antipsychotics
- Where
- 94 sites in Austria, Belgium and 23 more
- Volunteers
- 769 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia, Schizoaffective Disorder
Open-label Study of Curcumin C-3 Complex in Schizophrenia
Current evidence suggests that schizophrenia as a serious and complex psychiatric disorder, continues to challenge mental health professionals in their search for better treatment options in the community.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depression
- Trial name
- NCT01875822
- Testing
- Super-Curcumin
- Where
- Puerto Rico
- Volunteers
- 17 people
- Sponsor
- Woodbury, Michel, M.D.
Schizophrenia
Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia
The purpose of the study is to investigate these effects of Second-Generation Antipsychotic (SGAs) on glucose and lipid metabolic parameters in patients with schizophrenia, and explore the relationship between genes polymorphisms…
- Trial name
- NCT02964923
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xijing Hospital
NSCLC Adenocarcinoma, Solid Tumor
Atamparib in Patients With Advanced Solid Tumors
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients…
- Trial name
- PARP7 (NCT07374419)
- Testing
- atamparib escalation levels, atamparib RP2D
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Nerviano Medical Sciences (Shanghai) Ltd.
Schizophrenia
Treating Schizophrenia by Correcting Abnormal Brain Development
The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during the early course of schizophrenia can fundamentally correct the brain deficits associated with the disease.
- Trial name
- NCT00179465
- Testing
- Tiagabine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia
New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia
The purpose of this study is to: 1. Evaluate the efficacy and safety of the new antipsychotics, quetiapine (300-500mg/day) and risperidone (3-4mg/day) compared to each other and to fluphenazine (10-15mg/day), a high potency…
- Trial name
- NCT00161018
- Testing
- Quetiapine, Risperidone, Fluphenazine
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Maryland, Baltimore
Obesity, Mentally Ill Persons
Interactive Obesity Treatment Approach (iOTA) for Obesity Prevention in Serious Mental Illness
The proposed project aims to pilot and adapt a scalable and sustainable interactive obesity treatment approach (iOTA) program for adults with serious mental illness (SMI).
- Trial name
- iOTA-SMI (NCT03695289)
- Testing
- iOTA SMI, Health Education Control
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Cardiovascular Diseases (CVD), Depression Anxiety Disorder
Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)
Psycho-Cardiological Disease studies the complex links between the cardiovascular system and emotions. The two diseases are now the focus of public health organizations, forming a vicious circle of mutual influence.
- Trial name
- NCT07025590
- Testing
- Moderate-intensity continuous movement and Antipsychotics intervention, Antipsychotics intervention(sertraline, escitalopram, fluoxetine, duloxetine, paroxetine, venlafaxine, and fluvoxamine)
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Guangdong Provincial People's Hospital
First Episode Psychosis
Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication
The purpose of this study is to determine whether Vitamin B12,B6 and Folic Acid are effective with antipsychotic medication in the treatment of First Episode Psychosis.The B-complex Vitamins' homocysteine lowering properties may…
- Trial name
- NCT00202280
- Testing
- Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg
- Where
- Australia
- Volunteers
- 120 people
- Sponsor
- Melbourne Health
Schizophrenia
Study to Demonstrate Cognitive Enhancing Effects of BF2.649
To evaluate the cognitive enhancing effect of BF2.649 and to evaluate the effect of BF2.649 on symptom severity in persons with schizophrenia or schizoaffective disorder.
- Trial name
- NCT00690274
- Testing
- BF2.649
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia, Impaired Cognition
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies…
- Trial name
- NCT01714713
- Testing
- EVP-6124
- Where
- 128 sites in United States, Argentina and 14 more
- Volunteers
- 830 people
- Sponsor
- FORUM Pharmaceuticals Inc